Meta-analysis confirms CBD effectively reduces seizures in three pediatric epilepsy syndromes
Pooled analysis of 6 RCTs found CBD (Epidiolex) more than doubled the odds of 50% or greater seizure reduction across Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex.
Quick Facts
What This Study Found
CBD treatment was significantly more effective than placebo (OR=2.45, 95% CI: 1.81-3.32). Subgroup analysis showed benefit in all three syndromes: Dravet (OR=2.26), Lennox-Gastaut (OR=2.98), and tuberous sclerosis complex (OR=1.99). Higher adverse event rates were seen with CBD, especially with clobazam co-therapy.
Key Numbers
6 RCTs included. Pooled OR for 50%+ seizure reduction: 2.45 (p<0.01). By syndrome: Dravet 2.26, LGS 2.98, TSC 1.99. Adverse events increased (OR=1.81), serious adverse events (OR=2.86). Common side effects: diarrhea, somnolence, sedation.
How They Did This
Systematic review and meta-analysis of 6 RCTs meeting eligibility criteria from 1,183 screened articles. All studies used pharmaceutical-grade oral CBD (Epidiolex) at 10-50 mg/kg/day for up to 16 weeks. Subgroup analyses by syndrome and clobazam co-therapy.
Why This Research Matters
Refractory epilepsy in children is devastating and treatment options are limited. This meta-analysis strengthens the evidence base for CBD as both standalone and adjunct therapy across the three approved indications.
The Bigger Picture
CBD for pediatric epilepsy is one of the most well-studied cannabinoid medical applications. This meta-analysis reinforces that the benefits are real, while also highlighting the importance of managing side effects, particularly the drug interaction with clobazam.
What This Study Doesn't Tell Us
Only 6 RCTs available. All used one product (Epidiolex) at specific doses. Treatment duration limited to 16 weeks. Clobazam interaction complicates interpretation of whether CBD alone or the CBD-clobazam combination drives efficacy. Increased serious adverse events warrant careful monitoring.
Questions This Raises
- ?How much of the seizure reduction is attributable to the CBD-clobazam interaction vs. CBD alone?
- ?What are the optimal long-term dosing strategies beyond 16 weeks?
Trust & Context
- Key Stat:
- CBD more than doubled odds of 50%+ seizure reduction (OR=2.45, p<0.01)
- Evidence Grade:
- Meta-analysis of 6 low-risk-of-bias RCTs. High-quality evidence for the approved indications, though limited to one pharmaceutical product.
- Study Age:
- Published 2023.
- Original Title:
- Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.
- Published In:
- Experimental neurology, 359, 114238 (2023)
- Database ID:
- RTHC-04975
Evidence Hierarchy
Combines results from multiple studies to find an overall pattern.
What do these levels mean? →Frequently Asked Questions
How effective is CBD for childhood epilepsy?
In this meta-analysis, children receiving CBD were more than twice as likely to achieve 50% or greater seizure reduction compared to placebo across three difficult-to-treat epilepsy syndromes. The strongest effect was seen in Lennox-Gastaut syndrome (OR=2.98).
What are the risks of CBD for epilepsy?
CBD increased the odds of adverse events (OR=1.81) and serious adverse events (OR=2.86) compared to placebo. The most common side effects were diarrhea, somnolence, and sedation. The interaction between CBD and clobazam (a common co-prescribed medication) contributed significantly to both increased efficacy and side effects.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-04975APA
Talwar, Ashna; Estes, Emily; Aparasu, Rajender; Reddy, Doodipala Samba. (2023). Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.. Experimental neurology, 359, 114238. https://doi.org/10.1016/j.expneurol.2022.114238
MLA
Talwar, Ashna, et al. "Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.." Experimental neurology, 2023. https://doi.org/10.1016/j.expneurol.2022.114238
RethinkTHC
RethinkTHC Research Database. "Clinical efficacy and safety of cannabidiol for pediatric re..." RTHC-04975. Retrieved from https://rethinkthc.com/research/talwar-2023-clinical-efficacy-and-safety
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.